



# **Tuberculosis Country Profile 2021 Japan**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Japan

Population 2020: 126 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	15 000 (13 000-17 000)	12 (9.9-13)
HIV-positive TB incidence	77 (27-150)	0.06 (0.02-0.12)
HIV-negative TB mortality	3 500 (3 300-3 700)	2.8 (2.6-2.9)
HIV-positive TB mortality	14 (4-29)	0.01 (0-0.02)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	24% (20-28)

## TB case notifications, 2020

Total new and relapse	12 739
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	6.9%
- % pulmonary	74%
- % bacteriologically confirmed <sup>A</sup>	87%
- % children aged 0-14 years	<1%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	59%
Total cases notified	12 739

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	31	3.5%
- on antiretroviral therapy		

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>A</sup>	64%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>A</sup>	58%
Laboratory-confirmed cases - MDR/RR-TB <sup>AA</sup>	65
Patients started on treatment - MDR/RR-TB <sup>AAA</sup>	49
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>AA</sup>	
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>AAA</sup>	
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	66%	14 422
Previously treated cases, excluding relapse, registered in 2019		
HIV-positive TB cases registered in 2019	62%	29
MDR/RR-TB cases started on second-line treatment in 2018	67%	66
XDR-TB cases started on second-line treatment in 2018		

## TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	56% (41-86)

## TB financing


National TB budget, 2021 (US\$ millions)	43
--	----

\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
 \*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
<sup>A</sup> Calculated for pulmonary cases only  
<sup>AA</sup> Includes cases with unknown previous TB treatment history  
<sup>AAA</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



## HIV-negative TB mortality (Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2020 (Number)



## Cases attributable to five risk factors, 2020 (Number)

